keyword
MENU ▼
Read by QxMD icon Read
search

pancreatic adenocarcinoma chemotherapy

keyword
https://www.readbyqxmd.com/read/29454229/pancreatic-cancer-presenting-as-colonic-disease-a-rare-case-report
#1
Sara Tavares Nogueira, Bruno Lima Pinto, Eduardo Faria Silva, Hermano Anjos Garcia, Francisco Carneiro
INTRODUCTION: Pancreatic cancer is the fourth major cause of cancer-related deaths. About 50% of the patients are diagnosed with advanced disease. Metastatic disease to the colon is a very rare entity with only 5 cases described in english literature. CASE PRESENTATION: Male, 60 years-old, presents to a surgical consult with the diagnosis of an adenocarcinoma of the sigmoid colon. The physical exam revealed a periumbilical nodule with suspicious features. The staging CT-scan showed a mass in the tail of the pancreas involving the spleen and left kidney, thickening of the sigmoid colon, multiple mesenteric masses and trabecular changes in the ischium, suggesting metastatic disease...
February 9, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29438178/treatment-of-pancreatic-cancer-with-intravenous-vitamin-c-a-case-report
#2
Jeanne A Drisko, Oscar K Serrano, Lisa R Spruce, Qi Chen, Mark Levine
Pancreatic ductal adenocarcinoma (PDA) has a dismal prognosis and is often discovered at an advanced stage with few therapeutic options. Current conventional regimens for PDA are associated with significant morbidity, decreased quality of life, and a considerable financial burden. As a result, some patients turn to integrative medicine therapies as an alternate option after a diagnosis of PDA. Intravenous pharmacologic ascorbic acid (PAA) is one such treatment. The use of PAA has been passionately debated for many years, but more recent rigorous scientific research has shown that there are significant blood concentration differences when ascorbic acid is given parenterally when compared to oral dosing...
February 12, 2018: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29435178/inhibition-of-the-mek-erk-pathway-augments-nab-paclitaxel-based-chemotherapy-effects-in-preclinical-models-of-pancreatic-cancer
#3
Niranjan Awasthi, Sheena Monahan, Alexis Stefaniak, Margaret A Schwarz, Roderich E Schwarz
Nab-paclitaxel (NPT) combination with gemcitabine (Gem) represents the standard chemotherapy for pancreatic ductal adenocarcinoma (PDAC). Genetic alterations of the RAS/RAF/MEK/ERK (MAPK) signaling pathway yielding constitutive activation of the ERK cascade have been implicated as drivers of PDAC. Inhibition of downstream targets in the RAS-MAPK cascade such as MEK remains a promising therapeutic strategy. The efficacy of trametinib (Tra), a small molecule inhibitor of MEK1/2 kinase activity, in combination with nab-paclitaxel-based chemotherapy was evaluated in preclinical models of PDAC...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29435134/silver-nanoparticles-of-different-sizes-induce-a-mixed-type-of-programmed-cell-death-in-human-pancreatic-ductal-adenocarcinoma
#4
Ewelina Zielinska, Agata Zauszkiewicz-Pawlak, Michal Wojcik, Iwona Inkielewicz-Stepniak
Pancreatic ductal adenocarcinoma, with the high resistance to chemotherapeutic agents, remains the fourth leading cause of cancer-death in the world. Due to the wide range of biological activity and unique properties, silver nanoparticles (AgNPs) are indicated as agents with potential to overcome barriers involved in chemotherapy failure. Therefore, in our study we decided to assess the ability of AgNPs to kill pancreatic cancer cells, and then to identify the molecular mechanism underlying this effect. Moreover, we evaluated the cytotoxicity of AgNPs against non-tumor cell of the same tissue (hTERT-HPNE cells) for comparison...
January 12, 2018: Oncotarget
https://www.readbyqxmd.com/read/29434962/electron-microscopic-analysis-of-different-cell-types-in-human-pancreatic-cancer-spheres
#5
Toshiyuki Ishiwata, Fumio Hasegawa, Masaki Michishita, Norihiko Sasaki, Naoshi Ishikawa, Kaiyo Takubo, Yoko Matsuda, Tomio Arai, Junko Aida
Cancer stem cells (CSCs), which are pluripotent and self-renewable, contribute to the initiation and metastasis of cancer, and are responsible for resistance to chemotherapy and radiation. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive type of cancer that is associated with a high incidence of distant metastasis and recurrence. Sphere formation reveals cell proliferation under nonadherent conditions and is commonly used to identify CSCs; measurements of the number, area and volume of the spheres are used to estimate stemness of PDAC cells...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29434927/upregulation-of-pyruvate-kinase-m2-expression-by-fatty-acid-synthase-contributes-to-gemcitabine-resistance-in-pancreatic-cancer
#6
Shenghua Tian, Pingping Li, Shi Sheng, Xin Jin
Pancreatic cancer has one of the highest mortality rates of all cancer types. Fatty acid synthase (FASN) is a multifunctional protein homodimer that can convert acetyl coenzyme A (CoA) and malonyl-CoA into palmitate, thus regulating lipogenesis. FASN overexpression has also been shown to cause resistance to gemcitabine, a chemotherapy treatment for pancreatic cancer; however, the mechanism by which this happens is unclear. Analysis of gene expression of FASN and pyruvate kinase M2 (PKM2) in pancreatic cancer was performed using Oncomine microarray gene expression datasets, which demonstrated that FASN and PKM2 were upregulated in pancreatic cancer compared with normal tissue...
February 2018: Oncology Letters
https://www.readbyqxmd.com/read/29416754/targeted-deep-sequencing-of-circulating-tumor-dna-in-metastatic-pancreatic-cancer
#7
Andreas W Berger, Daniel Schwerdel, Thomas J Ettrich, Alexander Hann, Stefan A Schmidt, Alexander Kleger, Ralf Marienfeld, Thomas Seufferlein
Purpose: Precision medicine in pancreatic ductal adenocarcinoma (PDAC) could be substantially supported by tools that allow to establish and monitor the molecular setup of the tumor. In particular, noninvasive approaches are desirable, but not validated. Characterization of circulating tumor DNA (ctDNA) may help to achieve this goal. Experimental Design: Blood samples from patients with metastatic PDAC prior to and during palliative treatment were collected. ctDNA and corresponding tumor tissue were analyzed by targeted next generation sequencing and droplet digital PCR for the 7 most frequently mutated genes in PDAC (TP53, SMAD4, CDKN2A, KRAS, APC, ATM, and FBXW7)...
January 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29415082/subid-a-non-median-dichotomization-tool-for-heterogeneous-populations-reveals-the-pan-cancer-significance-of-inpp4b-and-its-regulation-by-evi1-in-aml
#8
Irakli Dzneladze, John F Woolley, Carla Rossell, Youqi Han, Ayesha Rashid, Michael Jain, Jüri Reimand, Mark D Minden, Leonardo Salmena
Our previous studies demonstrated that INPP4B, a member of the PI3K/Akt signaling pathway, is overexpressed in a subset of AML patients and is associated with lower response to chemotherapy and shorter survival. INPP4B expression analysis in AML revealed a right skewed frequency distribution with 25% of patients expressing significantly higher levels than the majority. The 75% low/25% high cut-off revealed the prognostic power of INPP4B expression status in AML, which would not have been apparent with a standard median cut-off approach...
2018: PloS One
https://www.readbyqxmd.com/read/29413459/212pb-labeled-b7-h3-targeting-antibody-for-pancreatic-cancer-therapy-in-mouse-models
#9
Benjamin B Kasten, Abhishek Gangrade, Harrison Kim, Jinda Fan, Soldano Ferrone, Cristina R Ferrone, Kurt R Zinn, Donald J Buchsbaum
INTRODUCTION: We recently validated monoclonal antibody (mAb) 376.96 as an effective carrier for targeted α-particle radioimmunotherapy (RIT) with 212Pb in ovarian cancer mouse models. In this study, we tested the binding of radiolabeled mAb 376.96 to human pancreatic ductal adenocarcinoma (PDAC) cells and localization in xenografts in immune-deficient mice and evaluated 212Pb-labeled 376.96 (212Pb-376.96) for PDAC therapy. METHODS: In vitro Scatchard assays assessed the specific binding of 212Pb-376...
December 24, 2017: Nuclear Medicine and Biology
https://www.readbyqxmd.com/read/29409480/contrasting-roles-of-h3k4me3-and-h3k9me3-in-regulation-of-apoptosis-and-gemcitabine-resistance-in-human-pancreatic-cancer-cells
#10
Chunwan Lu, Dafeng Yang, Maria E Sabbatini, Aaron H Colby, Mark W Grinstaff, Nicholas H Oberlies, Cedric Pearce, Kebin Liu
BACKGROUND: Pancreas ductal adenocarcinoma (PDAC) has the most dismal prognosis among all human cancers since it is highly resistant to chemotherapy, radiotherapy and immunotherapy. The anticipated consequence of all therapies is induction of tumor apoptosis. The highly resistance nature of PDACs to all therapies suggests that the intrinsic tumor cell factors, likely the deregulated apoptosis pathway, are key mechanisms underlying PDAC non-response to these therapies, rather than the therapeutic agents themselves...
February 6, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29404819/significance-of-glucose-transporter-type-1-glut-1-expression-in-the-therapeutic-strategy-for-pancreatic-ductal-adenocarcinoma
#11
Hiroshi Kurahara, Kosei Maemura, Yuko Mataki, Masahiko Sakoda, Satoshi Iino, Yota Kawasaki, Takaaki Arigami, Shinichiro Mori, Yuko Kijima, Shinichi Ueno, Hiroyuki Shinchi, Shoji Natsugoe
BACKGROUND: This study aimed to examine the prognostic relevance of glucose transporter type 1 (GLUT-1), which is a key regulator of the glucose metabolism. In particular, the study aimed to examine the association between GLUT-1 expression and the therapeutic effect of chemoradiotherapy (CRT) in pancreatic ductal adenocarcinoma (PDAC). METHODS: Patients with PDAC were enrolled in the study. Patients with distant metastases and those who received only chemotherapy as treatment were excluded from the study...
February 5, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29401167/the-association-of-recently-diagnosed-diabetes-and-long-term-diabetes-with-survival-in-pancreatic-cancer-patients-a-pooled-analysis
#12
Christie Y Jeon, Donghui Li, Sean Cleary, Rachael Stolzenberg-Solomon, Cristina Bosetti, Carlo La Vecchia, Miquel Porta, Adetunji T Toriola, Rayjean J Hung, Robert C Kurtz, Sara H Olson
OBJECTIVES: It is unclear whether long-standing diabetes or new-onset pancreatogenic diabetes contributes to poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: We investigated the influence of diabetes diagnosed shortly before PDAC and long-term diabetes on overall survival in 2792 PDAC patients who had participated in 3 PDAC case-control studies in the Pancreatic Cancer Case-Control Consortium. There were 300 patients with long-term diabetes of more than 3 years' duration (11%) and 418 patients with recently diagnosed diabetes of 3-year duration or less (15%)...
March 2018: Pancreas
https://www.readbyqxmd.com/read/29395234/postoperative-complications-after-resection-of-borderline-resectable-and-locally-advanced-pancreatic-cancer-the-impact-of-neoadjuvant-chemotherapy-with-conventional-radiation-or-stereotactic-body-radiation-therapy
#13
Alex B Blair, Lauren M Rosati, Neda Rezaee, Georgios Gemenetzis, Lei Zheng, Ralph H Hruban, John L Cameron, Matthew J Weiss, Christopher L Wolfgang, Joseph M Herman, Jin He
BACKGROUND: The impact of neoadjuvant stereotactic body radiation therapy on postoperative complications for patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma remains unclear. Limited studies have compared neoadjuvant stereotactic body radiation therapy versus conventional chemoradiation therapy. A retrospective study was performed to determine if perioperative complications were different among patients with borderline resectable or locally advanced pancreatic ductal adenocarcinoma receiving neoadjuvant stereotactic body radiation therapy or chemoradiation therapy...
January 25, 2018: Surgery
https://www.readbyqxmd.com/read/29394852/-a-case-report-of-curative-surgery-for-pancreatic-ductal-adenocarcinoma-with-peritoneal-dissemination-after-gemcitabine-chemotherapy
#14
Yoshitoshi Ichikawa, Daisaku Yamada, Hidetoshi Eguchi, Yoshifumi Iwagami, Takehiro Noda, Tadafumi Asaoka, Hiroshi Wada, Koichi Kawamoto, Kunihito Gotoh, Shogo Kobayashi, Mitsuaki Tatsumi, Misa Takeyari, Masaki Mori, Yuichiro Doki
A 70-year-old man was diagnosed with pancreatic ductal adenocarcinoma(PDAC)with peritoneal dissemination and received systemic chemotherapy of gemcitabine(GEM)plus nab-paclitaxel. Since the patient could not continue the regimen due to an adverse event of liver dysfunction, he was administered GEM alone except for the first administration. GEM monotherapy resulted in remarkable anti-tumor effects with a distinct decrease of both tumor markers and size. Peritoneal metastases were not detected in images after 12 courses of the GEM regimen, and the vanished tumor metastasis in images was maintained until 16 courses were administered...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394848/-a-case-of-urothelial-carcinoma-who-underwent-pancreaticoduodenectomy-and-was-diagnosed-with-groove-pancreatitis-and-preoperatively-suffered-from-duodenal-stenosis
#15
Daisuke Takiuchi, Osakuni Morimoto, Ryohei Wada, Masaya Higashiguchi, Takashi Nonoshita, Kentaro Nishida, Noriko Wada, Kazuya Sakata, Yusuke Akamaru, Hirofumi Ota, Kunitaka Shibata, Hirotsugu Ohashi
We report a case of a highly advanced urothelial carcinoma accompanied by duodenal stenosis with pancreaticoduodenectomy. A6 6-year-old man presented with upper abdominal pain and vomiting. Acute pancreatitis and hydronephrosis were diagnosed with urgent hospitalization, but jaundice appeared, and stenosis of the duodenum was also found. Thus, we suspected groove pancreatitis or pancreatic cancer, and performed pancreaticoduodenectomy. However, poorly differentiated adenocarcinoma was observed in the retroperitoneal dissection surface in the intraoperative rapid tissue and right hemicolectomy, right nephrectomy, and right ureteral resection were added to the diagnosis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394808/-long-term-survival-after-multidisciplinary-treatment-for-resected-pancreatic-adenocarcinoma-with-recurrence-of-pulmonary-metastases-a-case-report
#16
Tadashi Tsukamoto, Makoto Takahama, Shintaro Kodai, Akishige Kanazawa, Takaaki Hori, Ryoji Kaizaki, Satoshi Takatsuka, Ryushi Komatsu
Recent studies indicated that isolated pulmonary metastases could define a favorable subgroup in metastatic pancreatic cancer. We report a case of isolated pulmonary metastases after curative resection of pancreas head cancer treated with chemotherapy and pulmonary metastasectomy survived for 79 months after recurrence. A 72-year-old male underwent pancreatoduodenectomy for pancreas head cancer. Adjuvant chemotherapy was done with gemcitabine hydrochloride (GEM)for 6 months and then S-1 for 2 months. Twenty-seven months after surgery, 2 small metastatic nodules in the left lung was detected...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394807/-a-case-of-successful-adjuvant-surgery-for-the-pancreas-head-cancer-with-peritoneal-metastasis
#17
Yukie Kyakumoto, Tatsuyuki Takadate, Masamichi Mizuma, Tatsuo Hata, Masahiro Iseki, Hideo Ohtsuka, Naoaki Sakata, Kei Nakagawa, Takanori Morikawa, Hiroki Hayashi, Fuyuhiko Motoi, Takeshi Naitoh, Atsushi Kanno, Tooru Shimosegawa, Michiaki Unno
We report a case of the pancreas head cancer with peritoneal metastasis, which was resected curatively after chemotherapy. A6 6-year-old male was referred to our hospital for the treatment of biliary stenosis. The serum CA19-9 level was elevated and abdominal CT scan showed stenosis of distal bile duct. By laparotomy, we noticed mass in the head of the pancreas with 8mm of the seeding nodule in a diameter at jejunal mesentery which was diagnosed as adenocarcinoma by intraoperative frozen sections. Therefore, the patient was diagnosed as pancreas head cancer with peritoneal metastasis...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394696/-a-case-of-extragastric-developing-gastric-cancer-with-hepatic-and-pancreatic-invasion-suggesting-squamous-differentiation
#18
Norio Emoto, Yasunori Yoshimoto, Yusuke Sakamoto, Taku Nishimura, Yuichiro Kawamura, Takahisa Fujikawa, Akira Tanaka
A 69-year-old man presented with left upper abdominal pain and weight loss. Contrast-enhanced CT showed a 9 cmsized extragastric tumor located between the left lateral liver section and the gastric lesser curvature. Gastroendoscopy showed a type 3 tumor located at the lesser curvature of the antrum. Biopsy confirmed that the tumor was an adenocarcinoma. With a diagnosis of extragastric-developing gastric cancer with hepatic and pancreatic invasion, the patient underwent a totalgastrectomy, D2 lymph node dissection, partiall iver resection, and pancreatic body tailexcision...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394636/-an-enhanced-multimodality-treatment-strategy-in-pancreatic-ductal-carcinoma-requiring-heminephrectomy-for-radical-resection-a-case-report
#19
Akihiro Kitagawa, Yoshifumi Iwagami, Hidetoshi Eguchi, Daisaku Yamada, Tadafumi Asaoka, Takehiro Noda, Hiroshi Wada, Koichi Kawamoto, Kunihito Gotoh, Shogo Kobayashi, Masaki Mori, Yuichiro Doki
A 76-year-old male visited a clinic and the images incidentally revealed a tumor in the tail of pancreas. Pancreatic ductal adenocarcinoma was diagnosed by the following examination, indicating that the tumor invasion to spleen, left adrenal gland and left kidney(cT3N0M0, cStage II A), requiring heminephrectomy for radical resection. Enhanced preoperative treatments were performed while taking into account a possibility of any restrictions for the age and the standard adjuvant chemotherapies after heminephrectomy...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29394630/-neoadjuvant-folfirinox-for-unresectable-adenocarcinoma-of-the-pancreas-a-case-report
#20
Toshiya Ochiai, Hiroyuki Inoue, Hiroki Nakatsuji, Nobuyuki Watanabe, Atsushi Yoshiyama, Hiroshi Ito, Atsushi Toma, Kenji Nakamura
A 38-year-old male presented to our hospital with complaint of vomiting. A CT demonstrated a mass sized 42mm in the pancreatic head invading to the duodenum and a liver mass sized 15mm in the medial segment. Biopsy revealed adenocarcinoma. Due to liver metastasis, he was deemed surgically unresectable. He was started on FOLFIRINOX therapy after gastrojejunum bypass operation. After 15 courses of the therapy, restaging showed a decrease in pancreatic tumor size and a disappearance of a liver mass along with PET-CT revealing no FDG-avid uptake...
November 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
keyword
keyword
40926
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"